Eli Lilly's most recent trend suggests a bearish bias. One trading opportunity on Eli Lilly is a Bear Call Spread using a strike $170.00 short call and a strike $180.00 long call offers a potential 24.22% return on risk over the next 37 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $170.00 by expiration. The full premium credit of $1.95 would be kept by the premium seller. The risk of $8.05 would be incurred if the stock rose above the $180.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Eli Lilly is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Eli Lilly is bearish.
The RSI indicator is at 53.27 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Pharmas restart drug trials after pandemic-related declines, Medidata finds
Tue, 14 Jul 2020 01:47:12 +0000
The research, which was prepared by clinical trial technology company Medidata, shows that the number of new subjects entering trials increased 112% in June compared with the low point in April. Drugmakers around the world, including Eli Lilly & Co and Galapagos NV have announced plans to delay clinical trials for some drugs because of difficulties recruiting, treating and monitoring patients during the pandemic. In response, regulators, including the U.S. Food and Drug administration, have eased rules around collecting data remotely using digital tools to try to help drugmakers continue to research new treatments.
Have $5,000? 3 Coronavirus Stocks You Can Buy in July Without Losing Any Sleep
Sun, 12 Jul 2020 10:35:00 +0000
These healthcare leaders give you a relatively low-risk way to invest in the fight against COVID-19.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
Fri, 10 Jul 2020 15:30:03 +0000
Is (LLY) Outperforming Other Medical Stocks This Year?
Insiders Roundup: Mastercard, Eli Lilly
Fri, 10 Jul 2020 15:11:10 +0000
Largest insider trades of the week Continue reading…
New $1 bln fund aims to steer antibiotic companies in tough market
Thu, 09 Jul 2020 12:40:30 +0000
A new $1 billion fund backed by 20 drugmakers including Merck & Co Inc and Pfizer Inc is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments, an industry group said on Thursday. Public health authorities have raised alarms about a looming health crisis, saying deaths from antibiotic-resistant bacteria could dwarf that from the coronavirus pandemic. The new fund, led by the International Federation of Pharmaceutical Manufacturers & Associations, has raised nearly $1 billion so far and aims to help shore up investment in smaller biotech companies after several large drugmakers, such as Sanofi SA bowed out of the space.
Also on Market Tamer…
Follow Us on Facebook